Drug intelligence / Profile preview

VRON-0100

Development stage: Preclinical
Lead developer: Virion Therapeutics
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRON-0100 is a therapeutic cancer vaccine developed by Virion Therapeutics, a spin-out of The Wistar Institute. It is designed for the treatment of HPV-positive cancers. The vaccine incorporates a checkpoint modifier called gD that amplifies and broadens CD8+ T cell responses to disease-specific antigens, improving immunogenicity and efficacy in preclinical models. This checkpoint modification lowers the CD8+ T cell activation threshold, enhancing antiviral and antitumor immune responses compared to vaccines without gD. VRON-0100 is delivered using Virion's proprietary ChiVax™ platform technology.

Other names: VRON-0100VRON0100VRON 0100

Targets

TMEFF2BTLA

Beyond the preview

Go deeper on VRON-0100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRON-0100.

Explore the full profile